ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,996.47
0.45%
US Tech 100
20,302.80
0.35%
다우존스 지수
44,716.45
0.95%
Bitcoin
95,422.85
-2.67%
Registration Strip Icon for monitor 브라질 증권 거래소, NASDAQ, NYSE, AMEX, LSE 등 주요 거래소에서의 다양한 실시간 주식 시세를 모니터링합니다.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 유럽
  5. EU

  6. Adocia (ADOC) 시세

Adocia

Adocia (ADOC)

EU
7.72
-0.41
( -5.04% )
업데이트: 00:02:54
15분 지연

포트폴리오 강화: 실시간 토론 및 실행 가능한 거래 아이디어.

프리미엄

주요 통계 및 세부정보

가격
7.72
매수가
7.72
매도가
7.76
거래량
97,523
7.68 일간 변동폭 8.20
5.11 52주 범위 12.66
market_cap
111.157M
전일 종가
8.13
개장가
8.19
최근 거래 시간
200
@
7.72
마지막 거래 시간
00:02:54
재정 규모
-
VWAP
-
평균 볼륨(3m)
136,574
발행 주식
14,398,513
배당수익률
-
주가수익률
-5.25
주당순이익(EPS)
-1.47
매출
6.05M
순이익
-21.16M

Adocia 정보

섹터
Pharmaceutical Preparations
산업
Pharmaceutical Preparations
웹사이트
www.adocia.com
본부
Lyon, Rhone, Fra
설립됨
-
Adocia is listed in the Pharmaceutical Preparations sector of the 유로넥스트 (Euronext) with ticker ADOC. The last closing price for Adocia was 8.13 €. Over the last year, Adocia shares have traded in a share price range of 5.11 € to 12.66 €.

Adocia currently has 14,398,513 shares in issue. The market capitalisation of Adocia is 117.06 € million. Adocia has a price to earnings ratio (PE ratio) of -5.25.

ADOC 최신 뉴스

추가 뉴스

ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 31 octobre 2024

Regulatory News: Conformément aux dispositions de l’article L.233-8 II du Code de Commerce et de l’article 223-16 du Règlement Général de l’Autorité des Marchés Financiers (« AMF »). ADOCIA SA...

09 11월 2024
Business Wire

ADOCIA publie ses résultats financiers du troisième trimestre 2024 et fait le point sur ses activités

Position de trésorerie de 9,3 millions d’euros au 30 septembre 2024 Fin de l’étude de phase 3 sur BioChaperone® Lispro attendue en décembre 2024, étape associée à un paiement de 10 millions de...

31 10월 2024
Business Wire

ADOCIA annonce breveter des combinaisons stables d’analogues de GLP-1 et d’amyline pour le traitement de l’obésité et du diabète grâce à sa plateforme BioChaperone®

Adocia a déposé des demandes de brevet sur des combinaisons stables de semaglutide en combinaison avec le cagrilintide BioChaperone® CagriSema pourrait être administré dans tous les dispositifs...

15 10월 2024
Business Wire

Number of Shares and Voting Rights of ADOCIA as of September 30th, 2024

Regulatory News: Pursuant to the provisions of article L. 233-8 II of the French « Code de Commerce » and article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers...

09 10월 2024
Business Wire

ADOCIA annonce la mise à disposition de son Document d’Enregistrement Universel pour l’année 2021

Regulatory News: Adocia (Euronext Paris : FR0011184241 – ADOC), société biopharmaceutique au stade clinique spécialisée dans la recherche et le développement de solutions thérapeutiques...

26 4월 2022
Business Wire
기간변동변동 %시가고가저가평균 일일 거래량VWAP
1-0.31-3.860523038618.038.77.61622178.25797839DE
4-1.85-19.33124346929.5710.967.611674009.18920532DE
121.626.14379084976.1210.965.111365748.25305631DE
26-1.35-14.88423373769.0710.965.111283257.56276198DE
52-0.58-6.987951807238.312.665.111263418.62394061DE
156-0.94-10.85450346428.6616.162.745897948.08494568DE
260-1.12-12.66968325798.8416.182.745637318.29071605DE

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
ATOAtos SE
0.3535 €
(126.60%)
25.31M
ALIMOGroupimo
0.276 €
(46.03%)
100
ALROCRoctool
0.398 €
(36.30%)
261.93k
ALARFAdeunis
0.784 €
(20.99%)
2.94k
ALNMRNamR SA
0.46 €
(15.00%)
91
BIDSGascogne DS
0.003 €
(-40.00%)
75.69k
ALMERSapmer
6.40 €
(-14.67%)
2
ALBDMBD Multi-Media
1.14 €
(-11.97%)
204
ALDEVDevernois Sa
10.30 €
(-11.97%)
7
TVRBAction Televerbier
48.60 €
(-11.64%)
2
BCPBanco Comercial Portugues SA
0.45 €
(1.21%)
35.33M
ATOAtos SE
0.3535 €
(126.60%)
25.31M
ALNEVNeovacs
0.0002 €
(0.00%)
23.05M
ALTDTonner Drones
0.011 €
(10.00%)
12.83M
LATLatecoere
0.0075 €
(5.63%)
10.76M

토론

전체 피드 보기
Doc328 Doc328 3 분 전
Alzheimer's & Dementia would be a good journal to publish the study. They actually do recommend that the SAP be uploaded. However, the 2020 phase 2a paper did not include this in the supporting/supplementary data. The SAP / protocol for a phase 2 trial is less important as it is not a registrati
AVXL
GVInvestments GVInvestments 3 분 전
Thats great news, thanks for sharing. Can we get more information on there business friendship.
FNMA
tmcfo tmcfo 4 분 전
Company silence since the august post has been deafening..they must be too busy producing Xmax gifts for shareholders!
MVNT
JoJr JoJr 4 분 전
Full blown .0011's
Not the half baked .00105
Up 22%
RDAR
LarryBear40 LarryBear40 4 분 전
Yeah Nick, let me in please. @LarryAWood1

Thanks.
AAGC
Julesb Julesb 4 분 전
I just read the last paragraphs from large pharma companies quarterly meeting transcripts and majority of them including McKesson are looking to acquire companies. The pharma acquisition and merger forecast is forecast to be huge in 2025.

ELTP
Techroemancer Techroemancer 4 분 전
It says it right in the financials Steal,

$GEVI These conditions raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the consolidated financial statements are issued.

And the countdown begins
GEVI
williams45 williams45 4 분 전
$NNVC gains 2.81%, now $1.3776—progress fueling excitement!
https://iotracker96.com/Ry2vp
NNVC
KPIFF-LDDFF KPIFF-LDDFF 4 분 전
KPIFF
NewJerichoMan NewJerichoMan 4 분 전
Another tweet: https://x.com/BlueBiofuels/status/1861064314641125480
BIOF
trunkmonk trunkmonk 4 분 전
I hates gaps here, will this be a runaway gap, will volume sustain it, if not, fill and then go back up.
FNMA
glenn1919 glenn1919 4 분 전
VUZI..................MULN.......................https://stockcharts.com/h-sc/ui?s=MULN&p=W&b=5&g=0&id=p84354014936
MULN VUZI
Techroemancer Techroemancer 4 분 전
GEVI has ONLY 4 customers and Q1 only did GROSS revs of $400k and last 2 Qs tad over $100k gross revenue per Q, Lost 5 million and NOW GEVI as per S1 statement and what was stated in the recent Q subsequent events we can do the math and that GEVI is planning to sell their Offering of 3,500,000 to ra
GEVI
peanutz peanutz 4 분 전
I don't believe they do . They need some cheese to go with their " wine" LOL
IGPK
scotty3371 scotty3371 4 분 전
When shares trade on the offer they offer at a lower price, when shares trade on the bid, bid goes lower.

 
NWBO
barrydingle barrydingle 5 분 전
You want to reap a reward here?

You've been told how that can happen.
There is no Hans to file anything.

I believe the control person at MEDH is still listed as Jason Black.
I'd say the ball's in his court and he'd better play his hand with shareholders in
MEDH
govprs govprs 5 분 전
Benz selling? 
GDVM
Techroemancer Techroemancer 5 분 전
You still have 3 years per the requirements needed to uplist to NYSE. Below is some education material for you so that you can stop spreading misinformation.

• EARNINGS TEST: Adjusted pre -tax earnings from continuing operations must total (1) $10 million for the last three fiscal yea
GEVI
fink fink 5 분 전
Get burned that bad?

Wow!
IGPK
pos_stock_hoarder pos_stock_hoarder 5 분 전
From Stilton Jarlsberg:
https://blogger.googleusercontent.com/img/a/AVvXsEhYRzA5mGamEKIFwoNlJVqMhdpzLItTQ4F8YWJD5QDrtwpFkA8C9vDVBGu7_C-TVPYR1ktW0yOpMxqFMY8CUX90cYSDT2rpkC9WIxTE6ptGx_goTNUnqr7cy9nV_T5eAbwHTvXdyKoMVKIY-Vqywi3UYFqFTveMvIBIYsa2wdjVLDEyUx1_34GDmy2W07I=w640-h306

More
BIG BALLER BIG BALLER 5 분 전
Gary Gensler is useless , apparently schmoozing with the likes of Sam Bankman-Fried! :p ~realistically how could we expect anything to change under his watch?

...you wanna head the SEC next year? ;) cheers!
Guzzi62 Guzzi62 5 분 전
Our MC is now roughly 4X more than SAVA's

800 mill
200 mill

Biotech is incredibly brutal, and no mercy will be shown if you fail.
AVXL
Budots Budots 5 분 전
Adnexus Biotechnologies Inc., a staking target of 1606 Corp. (OTC PINK: $CBDW), has announced a game-changing merger with Sanctum Therapeutics. https://allcapresearch.com/f/adnexus-biotech-and-sanctum-merge-for-breakthrough-hiv-treatment
CBDW
Budots Budots 5 분 전
Adnexus Biotechnologies Inc., a staking target of 1606 Corp. (OTC PINK: $CBDW), has announced a game-changing merger with Sanctum Therapeutics. https://allcapresearch.com/f/adnexus-biotech-and-sanctum-merge-for-breakthrough-hiv-treatment
CBDW
BigBadWolf BigBadWolf 6 분 전
$RDAR 11's printed
RDAR

최근 히스토리

EU
ADOC
Adocia
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유